The impact of chemotherapy-naïve open radical cystectomy delay and perioperative transfusion on the recurrence-free survival: A perioperative parameters-based nomogram.
Autor: | Harraz AM; Urology and Nephrology Center, Mansoura University, Egypt., Elkarta A; Urology and Nephrology Center, Mansoura University, Egypt., Zahran MH; Urology and Nephrology Center, Mansoura University, Egypt., Mosbah A; Urology and Nephrology Center, Mansoura University, Egypt., Shaaban AA; Urology and Nephrology Center, Mansoura University, Egypt., Abol-Enein H; Urology and Nephrology Center, Mansoura University, Egypt. |
---|---|
Jazyk: | angličtina |
Zdroj: | Asian journal of urology [Asian J Urol] 2024 Apr; Vol. 11 (2), pp. 294-303. Date of Electronic Publication: 2022 Oct 17. |
DOI: | 10.1016/j.ajur.2022.09.002 |
Abstrakt: | Objective: To develop and internally validate a nomogram to predict recurrence-free survival (RFS) including the time to radical cystectomy (RC) and perioperative blood transfusion (PBT) as potential predictors. Methods: Patients who underwent open RC and ileal conduit between January 1996 to December 2016 were split into developing ( n =948) and validating ( n =237) cohorts. The time to radical cystectomy (TTC) was defined as the interval between the onset of symptoms and RC. The regression coefficients of the independent predictors obtained by Cox regression were used to construct the nomogram. Discrimination, validation, and clinical usefulness in the validation cohort were assessed by the area under the curve, the calibration plot, and decision curve analysis. Results: In the developing dataset, the 1-, 5-, and 10-year RFS were 83.0%, 47.2%, and 44.4%, respectively. On multivariate analysis, independent predictors were TTC (hazards ratio [HR] 1.07, 95% confidence interval [CI] 1.05-1.08, p <0.001), PBT (one unit: HR 1.40, 95% CI 1.03-1.90, p =0.03; two or more units: HR 1.72, 95% CI 1.29-2.29, p <0.001), bilateral hydronephrosis (HR 1.54, 95% CI 1.21-1.97, p <0.001), squamous cell carcinoma (HR 0.60, 95% CI 0.45-0.81, p =0.001), pT3-T4 (HR 1.77, 95% CI 1.41-2.22, p <0.001), lymph node status (HR 1.53, 95% CI 1.21-1.95, p <0.001), and lymphovascular invasion (HR 1.28, 95% CI 1.01-1.62, p =0.044). The areas under the curve in the validation dataset were 79.3%, 69.6%, and 76.2%, for 1-, 5-, and 10-year RFS, respectively. Calibration plots showed considerable correspondence between predicted and actual survival probabilities. The decision curve analysis revealed a better net benefit of the nomogram. Conclusion: A nomogram with good discrimination, validation, and clinical utility was constructed utilizing TTC and PBT in addition to standard pathological criteria. Competing Interests: The authors declare no conflict of interest. (© 2024 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |